Scientific Presentation | CTAD 2021
Phase 2/3 Trials of ATH-1017, a Novel Treatment Approach for Mild-to-Moderate Alzheimer’s Disease: Updates and Baseline Data
Xue Hua, Kevin Church, Kai-Bin Ooi, Joyce Maalouf, William Walker, Charles Bernick, Sam Dickson, Suzanne Hendrix, Larry Ereshefsky, and Hans J. Moebius
Download PDF
